BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 29042215)

  • 21. Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas.
    Giuliano S; Cheli Y; Ohanna M; Bonet C; Beuret L; Bille K; Loubat A; Hofman V; Hofman P; Ponzio G; Bahadoran P; Ballotti R; Bertolotto C
    Cancer Res; 2010 May; 70(9):3813-22. PubMed ID: 20388797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phosphatidylinositol 3-kinase-Pax3 axis regulates Brn-2 expression in melanoma.
    Bonvin E; Falletta P; Shaw H; Delmas V; Goding CR
    Mol Cell Biol; 2012 Nov; 32(22):4674-83. PubMed ID: 22988297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Automated in vivo screen in zebrafish identifies Clotrimazole as targeting a metabolic vulnerability in a melanoma model.
    Precazzini F; Pancher M; Gatto P; Tushe A; Adami V; Anelli V; Mione MC
    Dev Biol; 2020 Jan; 457(2):215-225. PubMed ID: 30998907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny.
    Cheli Y; Giuliano S; Botton T; Rocchi S; Hofman V; Hofman P; Bahadoran P; Bertolotto C; Ballotti R
    Oncogene; 2011 May; 30(20):2307-18. PubMed ID: 21278797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage.
    Yokoyama S; Feige E; Poling LL; Levy C; Widlund HR; Khaled M; Kung AL; Fisher DE
    Pigment Cell Melanoma Res; 2008 Aug; 21(4):457-63. PubMed ID: 18627530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential PAX3 functions in normal skin melanocytes and melanoma cells.
    Medic S; Rizos H; Ziman M
    Biochem Biophys Res Commun; 2011 Aug; 411(4):832-7. PubMed ID: 21802410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.
    Smith MP; Ferguson J; Arozarena I; Hayward R; Marais R; Chapman A; Hurlstone A; Wellbrock C
    J Natl Cancer Inst; 2013 Jan; 105(1):33-46. PubMed ID: 23250956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MED27 promotes melanoma growth by targeting AKT/MAPK and NF-κB/iNOS signaling pathways.
    Tang R; Xu X; Yang W; Yu W; Hou S; Xuan Y; Tang Z; Zhao S; Chen Y; Xiao X; Huang W; Guo W; Li M; Deng W
    Cancer Lett; 2016 Apr; 373(1):77-87. PubMed ID: 26797421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4.
    Mo X; Zhang H; Preston S; Martin K; Zhou B; Vadalia N; Gamero AM; Soboloff J; Tempera I; Zaidi MR
    Cancer Res; 2018 Jan; 78(2):436-450. PubMed ID: 29150430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Malignant melanoma and the role of the paradoxal protein Microphthalmia transcription factor].
    Denat L; Larue L
    Bull Cancer; 2007 Jan; 94(1):81-92. PubMed ID: 17237008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. STAT3 targeting by polyphenols: Novel therapeutic strategy for melanoma.
    Momtaz S; Niaz K; Maqbool F; Abdollahi M; Rastrelli L; Nabavi SM
    Biofactors; 2017 May; 43(3):347-370. PubMed ID: 27896891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Downregulation of α-Melanocyte-Stimulating Hormone-Induced Activation of the Pax3-MITF-Tyrosinase Axis by Sorghum Ethanolic Extract in B16F10 Melanoma Cells.
    Lee DH; Ahn SS; Kim JB; Lim Y; Lee YH; Shin SY
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29865165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chromatin remodellers Brg1 and Bptf are required for normal gene expression and progression of oncogenic Braf-driven mouse melanoma.
    Laurette P; Coassolo S; Davidson G; Michel I; Gambi G; Yao W; Sohier P; Li M; Mengus G; Larue L; Davidson I
    Cell Death Differ; 2020 Jan; 27(1):29-43. PubMed ID: 31065107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PPAR gamma regulates MITF and beta-catenin expression and promotes a differentiated phenotype in mouse melanoma S91.
    Grabacka M; Placha W; Urbanska K; Laidler P; Płonka PM; Reiss K
    Pigment Cell Melanoma Res; 2008 Jun; 21(3):388-96. PubMed ID: 18444964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Up-regulation of MET expression by alpha-melanocyte-stimulating hormone and MITF allows hepatocyte growth factor to protect melanocytes and melanoma cells from apoptosis.
    Beuret L; Flori E; Denoyelle C; Bille K; Busca R; Picardo M; Bertolotto C; Ballotti R
    J Biol Chem; 2007 May; 282(19):14140-7. PubMed ID: 17371876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential Prognostic Molecular Signatures in a Preclinical Model of Melanoma.
    Fortis SP; Anastasopoulou EA; Voutsas IF; Baxevanis CN; Perez SA; Mahaira LG
    Anticancer Res; 2017 Jan; 37(1):143-148. PubMed ID: 28011484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MITF suppression by CH5552074 inhibits cell growth in melanoma cells.
    Aida S; Sonobe Y; Yuhki M; Sakata K; Fujii T; Sakamoto H; Mizuno T
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1187-1193. PubMed ID: 28447210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GSK3beta inhibition promotes melanogenesis in mouse B16 melanoma cells and normal human melanocytes.
    Bellei B; Flori E; Izzo E; Maresca V; Picardo M
    Cell Signal; 2008 Oct; 20(10):1750-61. PubMed ID: 18602000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Negative Regulatory Loop between Microphthalmia-Associated Transcription Factor (MITF) and Notch Signaling.
    Golan T; Levy C
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30699982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5-Hydroxytryptamine (5-HT) Positively Regulates Pigmentation via Inducing Melanoblast Specification and Melanin Synthesis in Zebrafish Embryos.
    Liu L; Zhong M; Dong J; Chen M; Shang J; Yue Y
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32961761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.